BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAB Biotherapeutics (SABS)SAB BiotherapeuticsFinancing

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten

Open original release

Related news

SABSSAB Biotherapeutics2026-03-19 20:01 EST

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SABSSAB Biotherapeutics2026-03-18 02:46 EST

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

AVTXAvalo Therapeutics2026-05-05 20:05 EST

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CLDXCelldex Therapeutics2026-04-01 20:01 EST

Celldex Announces Proposed Public Offering of Common Stock

CLDXCelldex Therapeutics2026-04-06 14:53 EST

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CABACabaletta Bio2026-05-04 10:35 EST

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

ANABAnaptysBio, Inc.2026-03-27 13:00 EST

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

AVTXAvalo Therapeutics2026-05-06 03:33 EST

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

View all latest news

SAB Biotherapeutics

SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.

Recent company news

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SABSSAB Biotherapeutics2026-05-05 12:30 EST

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

Stock data

Close
3.44 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States